Trending - Altmetric
- Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific SymptomsLast mentioned on Mon Jan 17 2022
- U.S. FDA Drug Approvals for Breast Cancer — A Decade in ReviewLast mentioned on Wed Jan 05 2022
- From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research SummitLast mentioned on Thu Jan 06 2022
- Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation AnalysisLast mentioned on Sun Jan 16 2022
- Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway TargetingLast mentioned on Mon Jan 17 2022
- Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C InhibitionLast mentioned on Mon Jan 17 2022
- Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal MelanomaLast mentioned on Tue Jan 11 2022
- The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNALast mentioned on Fri Jan 14 2022
- Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)Last mentioned on Wed Jan 12 2022
- Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasisLast mentioned on Tue Jan 11 2022
- Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal CancerLast mentioned on Wed Jan 12 2022
- FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast CancerLast mentioned on Wed Jan 05 2022
- Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue SarcomaLast mentioned on Tue Dec 28 2021
- Long term follow-up and patterns of response, progression and hyperprogression in patients after PD-1 blockade in advanced sarcomaLast mentioned on Wed Jan 12 2022
Pages